MedWatch

Danish cancer vaccines receive million-grants and approach in-human trials

Biotech firm Adaptvac has received two grants for development of vaccines that can pave the way to the attractive cardiovascular disease- and breast cancer markets.

Foto: PR, ExpreS2ion

A new, effective and cheap vaccine may be under way for the more than 136 million cardiovascular patients all over the world. Also humans and dogs with HER2-positive cancer can maybe look forward to a new therapy.

Danish biotech company Adaptvac, a 50-50 joint venture between Nextgen Vaccines and Expres2ion Biotechnologies, recently received two grants for its vaccine programs from Innovation Fund Denmark.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier